Merck KGaA keeps US tariff surcharge while pausing China fees; cuts sales guidance to €20.9-22.4B amid economic uncertainty.

Biohaven said late Wednesday that the FDA would be delaying the PDUFA date for its neurodegenerative disease therapy ...

Jiang­su Hen­grui, a 55-year-old drug­mak­er that has be­come one of Chi­na’s lead­ing forces in biotech, ex­pects net pro­ceeds of about 9.4 bil­lion Hong Kong dol­lars … ...

HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare Therapeutics ...

The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

Three cell & gene therapy groups - ISCT, ARM & ASGCT - jointly call for 10-year global ban on human germline gene editing, ...

GSK to pay $1.2B upfront to Boston Pharmaceuticals for efimosfermin alfa, a MASH drug candidate. Deal includes $800M in ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...